Targeting of gut specific leucocyte recruitment in IBD by vedolizumab

Gut

Volumn 64, Issue 1, 2015, Pages 8-10

  Eksteen, Bertus ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; VEDOLIZUMAB; MONOCLONAL ANTIBODY;

ANTIGEN RECOGNITION; CELL INTERACTION; CELL MIGRATION; CROHN DISEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE MIGRATION; MUCOSAL IMMUNITY; NOTE; TREATMENT OUTCOME; ANTIBODY PRODUCTION; DRUG EFFECTS; FEMALE; GASTROINTESTINAL TRACT; IMMUNOLOGY; MALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; FEMALE; GASTROINTESTINAL TRACT; HUMANS; MALE;

EID: 84919772221     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307397     Document Type: Note

References (11)

1. Lobaton T, Vermeire S, Van Assche G, et al. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2014; 39: 579-94.
2. Agace WW Tissue-tropic effector T cells: generation and targeting opportunities. NatRevImmunol 2006; 6: 682-92.
3. Jaensson E, Uronen-Hansson H, Pabst O, et al. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. JExpMed 2008; 205: 2139-49.
4. Mora JR, Iwata M, Eksteen B, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006; 314: 1157-60.
5. Iwata M, Hirakiyama A, Eshima Y, et al. Retinoic Acid imprints gut-homing specificity on T cells. Immunity 2004; 21: 527-38.
6. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32.
7. Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. JClinInvest 1993; 92: 372-80.
8. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
9. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-21.
10. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Had Failed. Gastroenterology 2014. doi:10.1053/j.gastro.2014.05.008
11. Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 2015; 64: 77-83.